175 related articles for article (PubMed ID: 32618436)
1. Tumor rupture in hepatoblastoma: A high risk factor?
Pondrom M; Pariente D; Mallon B; Taque S; Branchereau S; Chardot C; Laithier V; Tabone MD; Lejeune J; Faure-Conter C; Saumet L; Vérité C; Aerts I; Brugières L; Fresneau B
Pediatr Blood Cancer; 2020 Sep; 67(9):e28549. PubMed ID: 32618436
[TBL] [Abstract][Full Text] [Related]
2. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
3. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J; Brugieres L; Brock P; Roebuck D; Maibach R; Zimmermann A; Childs M; Pariente D; Laithier V; Otte JB; Branchereau S; Aronson D; Rangaswami A; Ronghe M; Casanova M; Sullivan M; Morland B; Czauderna P; Perilongo G;
Lancet Oncol; 2013 Aug; 14(9):834-42. PubMed ID: 23831416
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.
Zsíros J; Maibach R; Shafford E; Brugieres L; Brock P; Czauderna P; Roebuck D; Childs M; Zimmermann A; Laithier V; Otte JB; de Camargo B; MacKinlay G; Scopinaro M; Aronson D; Plaschkes J; Perilongo G
J Clin Oncol; 2010 May; 28(15):2584-90. PubMed ID: 20406943
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong.
Liu APY; Ip JJK; Leung AWK; Luk CW; Li CH; Ho KKH; Lo R; Chan EKW; Chan ACY; Chung PHY; Chiang AKS
Pediatr Blood Cancer; 2019 Jan; 66(1):e27482. PubMed ID: 30270490
[TBL] [Abstract][Full Text] [Related]
6. Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL).
Semeraro M; Branchereau S; Maibach R; Zsiros J; Casanova M; Brock P; Domerg C; Aronson DC; Zimmermann A; Laithier V; Childs M; Roebuck D; Perilongo G; Czauderna P; Brugieres L
Eur J Cancer; 2013 Mar; 49(4):915-22. PubMed ID: 23146961
[TBL] [Abstract][Full Text] [Related]
7. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.
Hishiki T; Matsunaga T; Sasaki F; Yano M; Ida K; Horie H; Kondo S; Watanabe K; Oue T; Tajiri T; Kamimatsuse A; Ohnuma N; Hiyama E
Pediatr Surg Int; 2011 Jan; 27(1):1-8. PubMed ID: 20922397
[TBL] [Abstract][Full Text] [Related]
8. Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.
Illiano M; Colinard M; Taque S; Mallon B; Larue C; Laithier V; Vérité-Goulard C; Sudour-Bonnange H; Faure-Conter C; Coze C; Aerts I; De Maricourt CD; Paillard C; Branchereau S; Brugières L; Fresneau B
Hepatol Int; 2022 Feb; 16(1):125-134. PubMed ID: 34506008
[TBL] [Abstract][Full Text] [Related]
9. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors.
Perilongo G; Brown J; Shafford E; Brock P; De Camargo B; Keeling JW; Vos A; Philips A; Pritchard J; Plaschkes J
Cancer; 2000 Oct; 89(8):1845-53. PubMed ID: 11042582
[TBL] [Abstract][Full Text] [Related]
10. Resectability and tumor response after preoperative chemotherapy in hepatoblastoma treated by the Japanese Study Group for Pediatric Liver Tumor (JPLT)-2 protocol.
Hiyama E; Hishiki T; Watanabe K; Ida K; Yano M; Oue T; Iehara T; Hoshino K; Koh K; Tanaka Y; Kurihara S; Ueda Y; Onitake Y
J Pediatr Surg; 2016 Dec; 51(12):2053-2057. PubMed ID: 27712887
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk-stratified approach.
Srinivasan S; Prasad M; Parambil BC; Shrimal A; Gollamudi VRM; Subramani V; Ramadwar M; Khanna N; Baheti AD; Gala K; Patil V; Laskar S; Qureshi S; Chinnaswamy G
Pediatr Blood Cancer; 2023 Jul; 70(7):e30302. PubMed ID: 37046413
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin-epirubicin regimen for the treatment of hepatoblastoma.
Blouin P; Brugières L; Tabone MD; Leverger G; Rubie H; Branchereau S; De Kraker J
Pediatr Blood Cancer; 2004 Feb; 42(2):149-54. PubMed ID: 14752879
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.
Perilongo G; Shafford E; Maibach R; Aronson D; Brugières L; Brock P; Childs M; Czauderna P; MacKinlay G; Otte JB; Pritchard J; Rondelli R; Scopinaro M; Staalman C; Plaschkes J;
Eur J Cancer; 2004 Feb; 40(3):411-21. PubMed ID: 14746860
[TBL] [Abstract][Full Text] [Related]
14. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor.
Sasaki F; Matsunaga T; Iwafuchi M; Hayashi Y; Ohkawa H; Ohira M; Okamatsu T; Sugito T; Tsuchida Y; Toyosaka A; Nagahara N; Nishihira H; Hata Y; Uchino J; Misugi K; Ohnuma N;
J Pediatr Surg; 2002 Jun; 37(6):851-6. PubMed ID: 12037748
[TBL] [Abstract][Full Text] [Related]
15. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.
Schnater JM; Aronson DC; Plaschkes J; Perilongo G; Brown J; Otte JB; Brugieres L; Czauderna P; MacKinlay G; Vos A
Cancer; 2002 Feb; 94(4):1111-20. PubMed ID: 11920482
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
Ortega JA; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Finegold MJ; Haas JE; King DR; Liu-Mares W; Sensel MG; Krailo MD
J Clin Oncol; 2000 Jul; 18(14):2665-75. PubMed ID: 10894865
[TBL] [Abstract][Full Text] [Related]
17. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.
Weeda VB; Murawski M; McCabe AJ; Maibach R; Brugières L; Roebuck D; Fabre M; Zimmermann A; Otte JB; Sullivan M; Perilongo G; Childs M; Brock P; Zsíros J; Plaschkes J; Czauderna P; Aronson DC
Eur J Cancer; 2013 Aug; 49(12):2698-704. PubMed ID: 23683550
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary management of hepatoblastoma in children: Experience from a developing country.
Shanmugam N; Scott JX; Kumar V; Vij M; Ramachandran P; Narasimhan G; Reddy MS; Kota V; Munirathnam D; Kelgeri C; Sundaram K; Rela M
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27781375
[TBL] [Abstract][Full Text] [Related]
19. Initial liver transplantation for unresectable hepatoblastoma after chemotherapy.
Héry G; Franchi-Abella S; Habes D; Brugières L; Martelli H; Fabre M; Pariente D; Gauthier F; Jacquemin E; Branchereau S
Pediatr Blood Cancer; 2011 Dec; 57(7):1270-5. PubMed ID: 21910210
[TBL] [Abstract][Full Text] [Related]
20. Hepatoblastoma--evolution of management and outcome and significance of histology of the resected tumor. A 31-year experience with 40 cases.
Davies JQ; de la Hall PM; Kaschula RO; Sinclair-Smith CC; Hartley P; Rode H; Millar AJ
J Pediatr Surg; 2004 Sep; 39(9):1321-7. PubMed ID: 15359384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
